New Hope for Ovarian Cancer Patients as Senaparib Gains NMPA Approval for Maintenance Therapy Senaparib, developed by IMPACT Therapeutics, is now approved in China for maintenance therapy in advanced ovarian cancer, marking a significant advancement.

New Hope for Ovarian Cancer Patients as Senaparib Gains NMPA Approval for Maintenance Therapy #China #Shanghai #Ovarian_Cancer #Senaparib #IMPACT_Therapeutics